Proclamation 7207.

4,334 words·~20 min read·/statutes-at-large/vol-113/proclamation-7207

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

113 STAT. 2105 Proclamation 7207 of July 1, 1999 To Extend Nondiscriminatory Treatment (Normal Trade Relations Treatment) to Products of Mongolia and To Implement an Agreement To Eliminate Tariffs on Certain Pharmaceuticals and Chemical Intermediates By the President of the United States of America A Proclamation 1. The United States has had in effect a bilateral Agreement on Trade Relations with Mongolia since 1991 and has provided normal trade relations treatment to the products of Mongolia since that time.

I have found Mongolia to be in full compliance with the freedom of emigration requirements of title IV of the Trade Act of 1974 (the "Trade Act") (19 U.S.C. 2432). 2. Pursuant to section 2424(b)(1) of Public Law 106–36, and having due regard for the findings of the Congress in section 2424(a) of said Law, I hereby determine that title IV of the Trade Act (19 U.S.C. 2431–2441) should no longer apply to Mongolia. 3. On November 13, 1998, members of the World Trade Organization (WTO), including the United States and 21 other major trading countries, announced in the WTO an agreement to eliminate tariffs on certain pharmaceuticals and chemical intermediates that were the subject of reciprocal duty elimination negotiations during the Uruguay Round of Multilateral Trade Negotiations (the "Uruguay Round").

A similar agreement between the United States and 16 other major trading countries eliminating tariffs on enumerated pharmaceuticals and chemical intermediates was implemented for the United States on April 1, 1997, by Proclamation 6982, adding such goods to the scope of the agreement on pharmaceutical products reached at the conclusion of the Uruguay Round and reflected in Schedule XX—United States of America, annexed to the Marrakesh Protocol to the General Agreement on Tariffs and Trade

(1994)(Schedule XX). 4. Section 111(b) of the Uruguay Round Agreements Act

(URAA)(19 U.S.C. 3521(b)) authorizes the President to proclaim the modification of any duty or staged rate reduction of any duty set forth in Schedule XX for products that were the subject of reciprocal duty elimination negotiations during the Uruguay Round, if the United States agrees to such action in a multilateral negotiation under the auspices of the WTO, and after compliance with the consultation and layover requirements of section 115 of the URAA (19 U.S.C. 3524). Section 111(b) also authorizes the President to proclaim such modifications as are necessary to reflect such duty treatment in Schedule XX by means of rectifications thereof. 5. On April 29, 1999, pursuant to section 115 of the URAA, the United States Trade Representative

(USTR)submitted a report to the Committee on Ways and Means of the House of Representatives and the Committee on Finance of the Senate ("the Committees") that sets forth the proposed tariff eliminations, together with the advice received from the appropriate private sector advisory committee and the United States International Trade Commission regarding the proposed tariff 113 STAT. 2106eliminations. During the 60-day period thereafter, the USTR consulted with the Committees on the proposed actions. 6. Section 604 of the Trade Act, as amended (19 U.S.C. 2483), authorizes the President to embody in the Harmonized Tariff Schedule of the United States

(HTS)the substance of the relevant provisions of that Act, and of other acts affecting import treatment, and actions thereunder, including the removal, modification, continuance, or imposition of any rate of duty or other import restriction. 7. Pursuant to section 111(b) of the URAA, I have determined that Schedule XX should be modified to reflect the implementation by the United States of the multilateral agreement on certain pharmaceuticals and chemical intermediates negotiated under the auspices of the WTO. In addition, I have determined that the pharmaceuticals appendix to the HTS should be modified to reflect the duty eliminations provided in such agreement, and to make certain minor technical corrections in the identification of particular products in order to ensure that products are accorded the intended duty treatment. NOW, THEREFORE, I, WILLIAM J. CLINTON, President of the United States of America, acting under the authority vested in me by the Constitution and the laws of the United States, including but not limited to section 2424(b)(2) of Public Law 106–36, section 111(b) of the URAA, and section 604 of the Trade Act, do hereby proclaim that:

(1)Nondiscriminatory treatment (normal trade relations treatment) shall be extended to the products of Mongolia, which shall no longer be subject to title IV of the Trade Act.

(2)The extension of nondiscriminatory treatment to the products of Mongolia shall be effective as of the date of signature of this proclamation.

(3)In order to implement the multilateral agreement negotiated under the auspices of the WTO to eliminate tariffs on certain pharmaceutical products and chemical intermediates, and to make technical corrections in the tariff treatment accorded to such products, the HTS is modified as set forth in the Annex to this proclamation.

(4)Such modifications to the HTS shall be effective with respect to articles entered, or withdrawn from warehouse for consumption, on or after the dates set forth in the Annex for the respective actions taken.

(5)Any provisions of previous proclamations and Executive orders that are inconsistent with the actions taken in this proclamation are superseded to the extent of such inconsistency. IN WITNESS WHEREOF, I have hereunto set my hand this first day of July, in the year of our Lord nineteen hundred and ninety-nine, and of the Independence of the United States of America the two hundred and twenty-third. WILLIAM J. CLINTON 113 STAT. 2107 ANNEX MODIFICATIONS TO THE HARMONIZED TARIFF SCHEDULE OF THE UNITED STATES The Harmonized Tariff Schedule of the United States

(HTS)is modified as provided herein, effective on the dates set forth for each annex section. Section A. Effective with respect to articles entered, or withdrawn from warehouse for consumption, on or after July 1, 1999, the following products are to be accorded duty-free treatment: 1. For subheadings 2905.22.50, 2910.30.00, 2921.43.40, 2922.19.20, 2924.29.05, and 2933.39.20, the Rates of Duty 1-Special subcolumn is modified by inserting, in alphabetical order, the symbol “K” in the parentheses following the “Free” rate of duty in such subcolumn tor each such subheading. 2. The Pharmaceutical Appendix to the HTS is modified as provided below: (a). Table 1 of the Appendix is modified by adding the following new INNs, in alphabetical order, in the “Product” column and their CAS numbers in the “CAS No.” column: Product CAS Number Product CAS Number “abacavir 136470-78-5 eperezolid 165800-04-4 abafungin 129639-79-8 eplerenone 107724-20-9 abarelix 183552-38-7 eptifibatide 148031-34-9 abiraterone 154229-19-3 fabesetron 129300-27-2 acreozast 123548-56-1 fandofloxacin 164150-99-6 agomelatine 138112-76-2 faralimomab 167816-91-3 alatrofloxacin 157182-32-6 fasidotril 135038-57-2 alinastine 154541-72-7 fasoracetam 110958-19-5 almotriptan 154323-57-6 felvizumab 167747-20-8 almurtide 61136-12-7 fexofenadine 83799-24-0 amelometasone 123013-22-9 fidarestat 136087-85-9 amlintide 122384-88-7 filaminast 141184-34-1 apadoline 135003-30-4 flibanserin 167933-07-5 arcitumomab 154361-48-5 follitropin beta 150490-84-9 aripiprazole 129722-12-9 fomivirsen 144245-52-3 arofylline 136145-07-8 forasartan 145216-43-9 aseripide 153242-02-5 foropafant 136468-36-5 asimadoline 153205-46-0 frovatriptan 158747-02-5 atiprimod 123018-47-3 fudosteine 13189-98-5 atizoram 135637-46-6 fulvestrant 129453-61-8 atliprofen 108912-17-0 furomine 142996-66-5 atreleuton 154355-76-7 gacyclidine 68134-81-6 aviptadil 40077-57-4 ganaxolone 38398-32-2 avitriptan 151140-96-4 gatifloxacin 160738-57-8 avorelin 140703-49-7 gavestinel 153436-22-7 avotermin 182212-66-4 glaspimod 134143-28-5 bamaquimast 135779-82-7 glufosfamide 132682-98-5 basiliximab 179045-86-4 hemoglobin crosfumaril 142261-03-8 becaplermin 165101-51-9 ibutamoren 159634-47-6 bectumomab 158318-63-9 icopezil 145508-78-7 belaperidone 156862-51-0 igovomab 171656-50-1 beloxepin 135928-30-2 indinavir 150378-17-9 bepotastine 125602-71-3 indisetron 141549-75-9 bibapcitide 153507-46-1 infliximab 170277-31-3 biricodar 159997-94-1 insulin aspart 116094-23-6 blonanserin 132810-10-7 insulin glargine 160337-95-1 brasofensine 171655-91-7 interferon alfacon-1 118390-30-0 brinzolamide 138890-62-7 iocanlidic acid (123 I) 74855-17-7 carafiban 177563-40-5 ioflupane (123 I) 155798-07-5 cariporide 159138-80-4 iometopane (123 I) 136794-86-0 cedelizumab 156586-90-2 ipamorelin 170851-70-4 ceftizoxime alapivoxil 135821-54-4 iroplact 154248-96-1 celgosivir 121104-96-9 israpafant 117279-73-9 cemadotin 159776-69-9 ivabradine 155974-00-8 cerivastatin 145599-86-6 keliximab 174722-30-6 cetermin 157238-32-9 lagatide 157476-77-2 cevimeline 107233-08-9 landiolol 133242-30-5 choriogonadotropin alfa 177073-44-8 lanepitant 170566-84-4 cizolirtine 142155-43-9 lasinavir 175385-62-3 clenoliximab 182912-58-9 ledoxantrone 113457-05-9 clevidipine 166432-28-6 lefradafiban 149503-79-7 clevudine 163252-36-6 levocetirizine 130018-77-8 colesevelam 182815-43-6 levosalbutamol 34391-04-3 dabelotine 118976-38-8 licostinel 153504-81-5 dalcotidine 120958-90-9 linetastine 159776-68-8 danaparoid sodium 83513-48-8 linezolid 165800-03-3 daniplestim 161753-30-6 lintitript 136381-85-6 dapitant 153438-49-4 lintuzumab 166089-32-3 declopramide 891-60-1 lirexapride 145414-12-6 deltibant 140661-97-8 lodenosine 110143-10-7 dexefaroxan 143249-88-1 lotrafiban 171049-14-2 dexsotalol 30236-32-9 lumefantrine 82186-77-4 donepezil 120014-06-4 lurtotecan 149882-10-0 dronedarone 141626-36-0 mazokalim 164178-54-5 droxinavir 159910-86-8 melagatran 159776-70-2 dutasteride 164656-23-9 meluadrine 134865-33-1 ecenofloxacin 162301-05-5 mespiperone (11 C) 94153-50-1 edrecolomab 156586-89-9 metesind 138384-68-6 efavirenz 154598-52-4 milacainide 141725-10-2 elacridar 143664-11-3 milameline 139886-32-1 eldacimibe 141993-70-6 eletriptan 143322-58-1 elinafide 162706-37-8 embusartan 156001-18-2 emoctakin 142298-00-8 eniluracil 59989-18-3 enlimomab pegol 169802-84-0 ensaculin 155773-59-4 113 STAT. 2108 Annex (con.)-2- Section A (con.) 2. (con.) (a). (con.) Product CAS Number Product CAS Number milfasartan 148564-47-0 ritonavir 155213-67-5 milodistim 137463-76-4 rituximab 174722-31-7 minalrestat 129688-50-2 rivastigmine 123441-03-2 minodronic acid 127657-42-5 rizatriptan 144034-80-0 miproxifene 129612-87-9 robalzotan 169758-66-1 mitiglinide 145375-43-5 roflumilast 162401-32-3 mivobulin 122332-18-7 rosiglitazone 122320-73-4 moxifloxacin 151096-09-2 roxifiban 170902-47-3 moxilubant 146978-48-5 rupatadine 158876-82-5 nagrestipen 166089-33-4 sabcomeline 159912-53-5 nateglimde 105816-04-4 samarium (153 Sm) lexidronam 154427-83-5 nelfmavir 159989-64-7 sampatrilat 129981-36-8 nelzarabine 121032-29-9 saredutant 142001-63-6 nepadutant 183747-35-5 scopinast 145574-90-9 nepafenac 78281-72-8 seocalcitol 134404-52-7 nepaprazole 156601-79-5 sevelamer 52757-95-6 nepicastat 173997-05-2 sibrafiban 172927-65-0 nerelimomab 162774-06-3 sildenafil 139755-83-2 nifekalant 130636-43-0 silperisone 140944-31-6 nolatrexed 147149-76-6 sinapultide 138531-07-4 nolpitantium besilate 155418-06-7 sinitrodil 143248-63-9 nonacog alfa 113478-33-4 sipatrigine 130800-90-7 oberadilol 114856-44-9 sitafloxacin 127254-12-0 omapatrilat 167305-00-2 sivelestat 127373-66-4 omiloxetine 176894-09-0 soretolide 130403-08-6 opanixil 152939-42-9 sulesomab 167747-19-5 opratonium iodide 146919-78-0 sunepitron 148408-65-5 oprelvekin 145941-26-0 taltirelin 103300-74-9 orazipone 137109-78-5 talviraline 169312-27-0 orbofiban 163250-90-6 targinine 17035-90-4 osanetant 160492-56-8 tasonermin 94948-59-1 osutidine 140695-21-2 tazomeline 131987-54-7 pagoclone 133737-32-3 technetium (99m Tc) nofetumomab merpentan 165942-79-0 palinavir 154612-39-2 palonosetron 135729-56-5 technetium (99m Tc) pintumomab 157476-76-1 pamaqueside 150332-35-7 technetium (99mTc) apcitide 178959-14-3 pamiteplase 151912-42-4 temiverine 173324-94-2 paricalcitol 131918-61-1 temocaprilat 110221-53-9 pegmusirudin 186638-10-8 terbogrel 149979-74-8 peldesine 133432-71-0 tererstigmine 147650-57-5 pelubiprofen 69956-77-0 ticolubant 154413-61-3 pemetrexed 137281-23-3 tifacogin 148883-56-1 perifosine 157716-52-4 tilnoprofen arbamel 159098-79-0 pexiganan 172820-23-4 tivirapine 137332-54-8 pibutidine 103922-33-4 tobicillin 151287-22-8 pifonakin 112721-39-8 trafermin 131094-16-1 pleconaril 153168-05-9 trastuzumab 180288-69-1 pralmorelin 158861-67-7 trecovirsen 148998-94-1 pramlintide 151126-32-8 tresperimus 160677-67-8 pranazepide 150408-73-4 upenazime 95268-62-5 pregabalin 148553-50-8 urokinase alfa 99821-47-3 prucalopride 179474-81-8 valganciclovir 175865-60-8 pumaprazole 158364-59-1 valnemulin 101312-92-9 quetiapine 111974-69-7 valspodar 121584-18-7 quilostigmine 139314-01-5 vatanidipine 116308-55-5 raltitrexed 112887-68-0 vedaclidine 141575-50-0 ranelic acid 135459-90-4 vinflunine 162652-95-1 rapacuronium bromide 156137-99-4 xaliproden 135354-02-8 resocortol 76675-97-3 xemilofiban 149820-74-6 retigabine 150812-12-7 ziconotide 107452-89-1 revatropate 149926-91-0 zinostatin stimalamer 123760-07-6 rifalazil 129791-92-0 zolmitriptan 139264-17-8” rismorelin 146706-68-5 (b). Table 2 of the Appendix is modified by adding the following chemical or INN derivative names in alphabetical order: " “BENZOATE MONOBENZOATE DIFUMARATE TETRAISOPROPYL” DIPIVOXIL " (c). Table 3 of the Appendix is modified by adding the following product names, in alphabetical order, along with their CAS numbers: Product CAS Number “(S)-but-3-yn-2-ol 2914-69-4 2-(4-fluorobenzyl)thiophene 63877-96-3 5-amino-N,N'-bis[2-acetoxy-1-.(acetoxymethyl)ethyl]-2,4,6-triiodoisophthalamide 148051-08-5 5-amino-N,N'-bis(2,3-dihyaroxypropyl)-2,4,6-triiodoisophthalamide 76801-93-9 (S)-alpha-chloroformylethyl acetate 36394-75-9 diethyl dipropylmalonate 6065-63-0 5-methyl-N-[4-(sulfamoyl)phenethyl]pyrazine-2-carboxamide 33288-71-0 (5aR,11bS)-9.10-dimetnoxy-2-propyl-4,5,5a,6,7,11b-hexahydrobenzo[f]thieno[2,3-c]-quinoline hydrochloride 178357-37-4 methyl N-(phenoxycarbonyl)-L-valinate 153441-77-1 (+-)-6-fluoro-1-methyl-4-oxo-7-(piperazin-1-yl)-4H-[1,3]thiazeto-[3,2-a]quinoline-3-carboxylic acid 112984-60-8 methyl 3-amino-4,6-dibromo-o-toluate 119916-05-1 4,6-dibromo-3-fluoro-o-toluic acid 119916-27-7 7-bromo-1 -cyclopropyl-6-fluoro-5-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 119916-34-6 113 STAT. 2109 Annex (con.)-3- Section A. (con.) 2. (con.) (c). (con.) Product CAS Number 2-mercapto-5-(trifluoromethyl)aniliniurn chloride 4274-38-8 2-(3-bromophenoxy)tetrahydropyran 57999-49-2 6-chloro-5-(2-chloroethyl)indol-2(3H)-one 118289-55-7 6-chloroindol-2(3H)-one 56341-37-8 6-methoxy-1,2,3,4-tetrahydro-1-naphthone 1078-19-9 N-[N-(tert-butoxycarbonyl)-L-alanyl]-L-alanine hydrate 90303-36-9 2,2'-dithiodibenzonitrile 33174-74-2 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]benzoic acid 194602-23-8 1-methyl-4-nitro-3-propylpyrazole-5-carboxamide 139756-01-7 (S)-2-(4-fluorophenyl)-3-methylbutyric acid 55332-37-1 [3-(benzimidazol-2-yl)propyl]methylamine 64137-52-6 7-chloro-5-(2-fluorqphenyl)-1 H-1,4-benzodiazepin-2(3H)-one 2886-65-9 2-bromo-4'-chloro-2'-(2-fiuorobenzoyl)acetanilide 1584-62-9 2'-benzoyl-2-bromo-4'-chloroacetanilide 41526-21-0 (RS)-sennohydrazide hydrochloride 55819-71-1 2,3,4-trihydroxybenzaldehyde 2144-08-3 dimethyl chloromalonate 28868-76-0 4,6-dicnloro-5-(2-methoxyphenoxy)-2,2'-bipyrimidinyl 150728-13-5 4-tert-butvlbenzenesulfonamide 6292-59-7 methyl 3-[(methoxycarbonylmethyl)sulfamoyllthiophene-2-carboxylate 106820-63-7 methyl 4-nydroxy-z-methyl-2H-thieno[2,3-eni,2]thiazine-3-carboxylate 1,1-dioxide 59804-25-0 tert-butyl (1S,9S)-6,10-dioxo-9-phthalimidooctahydropyridazo[1,2-a][1,2]diazepine-1-carboxylate 106928-72-7 ethyl (R)-2-hydroxy-4-phenylbutyrate 90315-82-5 1-benzyl hydrogen (S)-4-phthalimidoglutarate 88784-33-2 (S)-1-(benzy loxycarbonyl)hexahydropyridazine-3-carboxylic acid 65632-62-4 methyl {(1 S,2R)-1 -benzyl-3-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)decahydro-2-isoquinolyl]-2-hydroxypropyl}carbamate 178680-13-2 (3S,4aS,8aS)-2-[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]-N-tert-butyldecahydroisoquinoline-3-carboxamide 136522-17-3 4-[(S)-3-amino-2-oxopyrrolidin-1-yl)benzonitrile hydrochloride 175873-08-2 ethyl 3-(3-{(S)-1-[4-(N'2-hydroxyamidinolphenyl]-2-oxopyrrolidin-3-yl}ureido)propionate 175873-10-6 4-[5-(p-tolyl)-3-(tnfluoromethyl)-1H-pyrazol-1-yljoenzenesulfonamide 169590-42-5 4-nydrazonobenzenesulfonamide hydrocholoride 17852-52-7 4'-amidinosuccinanilic acid hydrochloride 149177-92-4 ethyl (S)-3-aminopent-4-ynoate hydrochloride 154772-45-9 11-alpba-hydroxy-7-alpha-(methoxycarbonyl)-3-oxopregn-4-ene-21,17-alpha-carbolactone 192704-56-6 11-alpha-hydroxy-3-oxopregna-4.6-diene-21,17-alpha-carbolactone 73726-56-4 4-(5-methyl-3-phenylisoxazol-4-yi)benzenesulfonamide 181695-72-7 5-methyl-3,4-diphenyl-4.5-dihydroisoxazol-5-ol 181696-73-1 N-[4-(5-methyl-3-phenylisoxazol-4-yl)phenylsulfonyl]propionamide, sodium salt 198470-85-8 pivaloyloxymethyl 7-{(Z)-2-[2-(tert-butoxycarbonylamino)thiazol-4-yl]pent-2-enamido}-3-(carbamoytoxymethyl)-3-cephem-4-carboxylate 105889-80-3 benznydryl 6-(4-methylbenzamido)penicillanic acid 4-oxide 77887-68-4 benzhydryl 7-{(Z)-2-[2-(tert-butoxycarbonylamino)thiazol-4-yl]-4-(3-methylbut-2-enyloxycarbonyl)but-2-enamido}-3-cephem-4-carboxylate 174761-17-2 N-(2-quinolylcarbonyl)-L-asparagine 136465-98-0 methyl N-(methoxycarbonyl)-L-pnenylalaninate 41844-71-7 N-[(2,6-diisopropylphenoxy)sulfonyll-2-(2,4.6-triisopropylphenyl)acetamide 166518-60-1 (2S,3S)-3-methyl-2-(3-oxo-2,3-dihyaro-1,2-benzisothiazol-2-yl)valeric acid 177785-47-6 (1S,4R)-1-azabicyclo[2.2.1]heptan-3-one O-[(Z)-(3-methoxyphenyl)ethynyl]oxime-maleic acid (1:1) 180050-34-4 N-[(R)-9-methyl-4-oxo-1-phenyl-3,4,6,7-tetranydro[1,4]diazepino[6,7,1-hi]indol-3-yl]isonicotinamide 179024-48-7 4-acetamido-2'-aminobenzanilide 112522-64-2 N,N'-bis[3-(ethylamino)propyl]propane-1,3-diamine tetrahydrochloride 156886-85-0 ethyl 5-(out-3-enyl)thiophene-2-carboxylate 208337-82-0 ethyl 5-(3R)-3,4-dihydroxybutyllthiophene-2-carboxylate 208337-83-1 ethyl 5-(3R)-4-amino-3-hydroxybutyl]thiophene-2-carboxylate 208337-84-2 ethyl 5-(3R)-4-(tert-butoxycarbonylamino)-3-hydroxybutyl]thiophene-2-carboxylate 186521-38-0 ethyl 5-(3R)-4-(tert-butoxycarbonylamino)-3-(mesyloxy)butyl]thiophene-2-carboxylate 186521-39-1 ethyl 5-[(3S)-3-(acetylthio)-4-(tert-butoxycarbonylamino)butyl]thiophene-2-carboxylate 186521-40-4 dimethyl 2-[(S)-1-(tert-butoxycarbonylaminomethyl)-2-(5-ethoxycarbonyl-2-thienyl)propylthio] malonate 186521-41-5 methyl (S)-6-{2-[5-ethoxycarbonyl)-2-thienyl]ethyl}-3-oxo-1,4-thiazinane-2-carboxylate 186521-42-6 ethyl (6S)-5-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimido[5,4-b][1,4]thiazin-6-yl)ethyl] thiophene-2-carboxylate 186521-44-8 (6S)-5-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimido[5,4-b][1,4]thiazin-6-yl)ethyl]thiophene-2-carboxylic acid 186521-45-9 diethyl N-[5-T2-((6S)-2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimido[5,4-b][1,4]thiazin-6-yl)-ethyl]-2-thenoyl)-L-glutamate 177575-19-8 4-chloropyridine hydrochloride 7379-35-3 4-phenoxypyridine 4783-86-2 4-(4-pyridyloxy)benzenesulfonic acid 192329-80-9 4-(4-pyridyloxy)benzenesulfonyl chloride hydrochloride 192330-49-7 (3S)-2,2-dimethyl-1,4-thiazinane-3-carboxylic acid 84915-43-5 (3S)-2,2-dimethyl-4-[4-(4-pyridyloxy)phenylsulfonyl]-1,4-thiazinane-3-carboxylic acid 192329-83-2 2-amino-5-bromo-6-methylquinazolin-4(1H)-one 147149-89-1 3-acetoxy-o-toluic acid 168899-58-9 (4R,5R)-4,5-bis(mesyloxymethyl)-1,3,2-dioxathiolane 2,2-dioxide 208338-09-4 (2R,3R)-1,4-bis(mesyloxy)butane-2,3-diol 1947-62-2 3,7,11-trimethyldodeca-1,6,10-trien-3-ol 7212-44-4 (6E, 10E, 14E)-3,7,11,15-tetramethylhexadeca-1,6,10,14-tetraen-3-ol 1113-21-9 methyl 4-amino-5-nitro-o-anisate 59338-84-0 methyl 5-(ethylsulfonyl)-o-anisate 62140-67-4 methyl 5-sulfamoyl-o-anisate 33045-52-2 3-methoxy-5-sulfamoyl-o-anisic acid 66644-80-2 1-benzylpjperidine-4-carbaldehyde 22065-85-6 {(E)-3-[(6R,7R)-7-amino-2-carboxylato-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]allyl)-(carbamoylmethyl)(ethyl)methylammonium 160115-08-2 [4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methanol 118175-10-3 (Z)-2-(5-amino-1,2,4-tniadiazol-3-yl)-2-[(rluoromethoxy)imino]acetic acid 116833-10-4 2-(ethylmethylamino)acetamide 116833-20-6 4-chloro-2-[(Z)-(methoxycarbonyl)methoxyimino]-3-oxobutyric acid 84080-70-6 2-(5-ethyl-2-pyridyl)ethanol 5223-06-3 2-(4-aminophenoxymethyl)-2,5,7,8-tetramethyl-4-oxochroman-6-yl acetate 107188-37-4 chloromethyl pivalate 18997-19-8 7-ethyl-3-[2-(trimethylsilyloxy)ethyllindole 185453-89-8 5-amino-2,4,6-triiodoisophthalic acid 35453-19-1 4-hydroxyindole 2380-94-1 thiazolidine-2,4-dione 2295-31-0 2-bromo-3-methylthiophene 14282-76-9 5-methyluracil 65-71-4 113 STAT. 2110 Annex (con.) -4- Section A. (con.) 2. (con.) (c). (con.) Product CAS Number thymidine 50-89-5 3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridylmethanol 103577-66-8 3-(cyanoimino)-3-piperidinopropiononitrile 56488-00-7 N-acetyl-3-(3,4-dimethoxypnenyl)-DL-alanine 27313-65-1 2,5,7,8-tetramethyl-2-(4-niirophenoxymethyl)-4-oxochroman-6-yl acetate 107188-34-1 methyl 4-(bromomethyl)-m-anisate 70264-94-7 9-bromononyl 4,4,5,5,5-pentafluoropentyl sulfide 148757-89-5 2-(phenylthio)aniline 1134-94-7 4,4,5,5,5-pentafluoropentan-1-ol 148043-73-6 methyl (S)-2-amino-4-(1H-tetrazol-5-yl)butyrate 127105-49-1 (3-chloro-4-fluorophenyl)[7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-yl]amine 184475-35-2 5-hydroxy-1,2,3,4-tetrahydro-1 -napnthone 28315-93-7 (R)-1-chloro-2,3-epoxypropane 51594-55-9 methyl 4-acetamido-o-anisate 4093-29-2 4-acetamido-5-chloro-o-anisic acid 24201-13-6 methyl (1S,2S)-1-benzyl-3-chloro-2-hydroxypropylcarbamate 176972-62-6 ethyl 2-chloronicotinate 1452-94-4 ethyl 6-chloronicotinate 49608-01-7 6-hydroxynicotinic acid 5006-66-6 6-cnloronicotinic acid 5326-23-6 1-acetylpiperazine 13889-98-0 8-azaspiro[4.5]decane-7,9-dione 1075-89-4 (S)-2-(4-{[(2,7-dimethyl-4-oxo-1,4-dihydroquinazolin-6-yl)methyl](prop-2-ynyl)ammo}-2-fluorobenzamido)-4-(1 H-tetrazol-5-yl)butyric acid 153537-73-6 SC-59735 116638-33-6 SC-70935 193700-51-5 6,7-dichloro-2,3-dimethoxyquinoxalin-5-ylamine 178619-89-1 4-(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)benzoic acid 132026-12-1 methyl(4'-nitrophenethyl)amine hydrochloride 166943-39-1 2-chloroethyl 4-nitrophenyl ether 3383-72-0 (2RS,3SR)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol-(1R,4S)-2-oxobornane-10-sulfonic acid (1:1) 188416-34-4 6-ethyl-5-fluoropyrimidin-4(1H)-one 137234-87-8 diphenyl[(S)-pyrrolidin-3-yl]acetonitrile hydrobromide 194602-27-2 (2,3-dihyarobenzofuran-5-yl)acetic acid 69999-16-2 cyclohexylammonium 1-[(S)-2-(tert-butoxycarbonyl)-3-(2-methoxyethoxy)propyl]-cyclopentanecarboxylate 167944-94-7 cis-4-(benzyloxycarbonyl)cyclohexylammonium tosylate 67299-45-0 5-bromo-3-[(R)-1-methylpyrrolidin-2-ylmethyl]indole 143322-57-0 meso-3-benzyl-6-nitro-3-azabicyclo[3.1.0]hexane 151860-16-1 diethyl (6-chloro-9H-carbazol-2-yl)methylmalonate 71208-55-4 beta-cyclodextrin sulfobutyl ethers, sodium salts 182410-00-0 N-(2-cnloroethyl)pyrrolidine hydrochloride 7250-67-1 6,7-bis(2-methoxyethoxy)quinazolin-4(1H)-one 179688-29-0 ethyl 3,4-dihydroxybenzoate 3943-89-3 3-{(Z)-1-[4-(2-dimethylaminoethoxy)phenyl]-2-phenylbut-1-enyl}phenol 83647-29-4 2-[1-(tert-butoxycarbonyl)-4-piperidyl]acetic acid 157688-46-5 4-pyridylacetic acid hydrochloride 6622-91-9 a,a,a-trifluoro-4-nitro-m-toluidine 393-11-3 methyl 1-(2,3,5-tri-O-acetyl-beta-D-ribofuranosyl)-1 H-1,2,4-triazole-3-carboxylate 39925-10-5 N'a-(tert-butoxycarbonyl)-N'w-nitro-L-arginine 2188-18-3 N'a-(tert-butoxycarbonyl)-N-methoxy-N-methyl-N'w-nitro-L-argininamide 139976-34-4 (2S,3S)-3-amino-2-ethoxy-N-nitropiperidine-1-carboxamidine hydrochloride 180250-77-5 (S)-O-benzyllactaldehyde-N-(tert-butoxycarbonyl)hydrazone 192802-28-1 phenyl {4-[4-(4-hydroxyphenyl)piperazin-1-yl]phenyl}carbamate 184177-81-9 [(3S,5S)-5-(2,4-difluorophenyl)-5-(1H-1,2,4-triazol-1-ylmethyl)tetrahydrofuran-3-yl]methyl-4-chlorooenzenesulfonate 175712-02-4 8-chloro-11-(4-piperidylidene)-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridine 100643-71-8 2-hydroxy-2-metnyl-4-nitro-3-(trifluoromethyl)propionanilide 52806-53-8 5-acetylsalicylamide 40187-51-7 8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-one 31251-41-9 1-nitro-4-(1,2,2.2-tetrachloroethyl)benzene 4714-32-3 3-chloropropyldimethylammonium chloride 5407-04-5 3-(trichlorovinyl)aniline hydrochloride 81972-27-2 2-[1-(mercaptomethyl)cyclopropyl]acetic acid 162515-68-6 3-(4-oromobenzyl)-2-butyl-4-chloro-1H-imidazol-5-ylmethanol 151015-31-6 4-chloro-1-methylpiperidine hydrochloride 5382-23-0 methyl 2-[(S)-3{(E)-3-[2-(7-chloro-2-quinolyl)vinyl]phenyl}-3-hydroxypropyl]benzoate 181139-72-0 methyl 2-(3-{(E)-3-[2-(7-chloro-2-quinolyl)vinyl]phenyl}-3-oxopropyl)benzoate 149968-11-6 2-(2-(rityl-2H-tetrazol-5-yl)phenylboronicacid 143722-25-2 (3aS,8aR)-3-[(2R,4S)-2-benzyl-4,5-epoxyvaleryl]-2,2-dimethyl-3,3a,8,8a-tetrahydro-2H-indeno[1,2-d]oxazole 158512-24-4 N-[(4S,6S)-6-methyl-7,7-dioxo-5,6-dihydro-4H-thieno[2,3-b]thiopyran-4-yl]acetamide 147086-83-7 N-[(4S,6S)-6-methyl-7,7-dioxo-2-sulfamoyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-4-yl] acetamide 147200-03-1 5-iodouracil 696-07-1 N'1-methyl-1H-pyrazole-1-carboxamidine hydrochloride 59194-35-3 (S)-tetrahydrofuran-3-ol 86087-23-2 ethyl 4,6-dichloro-3-formylindole-2-carboxylate 153435-96-2 3-oxoandrost-4-ene-17-beta-carboxylic acid 302-97-6 alpha, alpha, alpha,alpha',alpha',alpha'-hexafluoro-2,5-xylidine 328-93-8 (±)-2-azabicyclo[2.2.1]hept-5-en-3-one 61865-48-3 (1R,4S)-2-azabicyclo[2.2.1]hept-5-en-3-one 79200-56-9 [(1 S,4R)-4-(2-amino-6-chloro-9H-purin-9-yl)cyclopent-2-enyl]methanol hydrochloride 172015-79-1 N-(2-amino-4,6-dichloropyrimidin-5-yl)formamide 171887-03-9 4-fluorobenzyl 4-(methyltnio)phenyl ketone 87483-29-2 2-amino-3-pyridyl methyl ketone 65326-33-2 6-methoxy-1H-purin-2-ylamine 20535-83-5 1-(beta-D-arabinofuranosyl)pyrimidine-2,4(1H,3H)-dione 3083-77-0 (2R)-4-methyl-2-[(S)-2.2-dimethyl-5-oxo-1,3-dioxolan-4-yl]valeric acid 157518-70-2 (S)-2-amino-3,3-dimetnyl-N-2-pyridylbutyramide 171764-07-1 3-nitro-4-pyridone 5435-54-1 2,6-difluorobenzylamine 69385-30-4 L-ribose 24259-59-4 (5,6-dichloro-1H-benzimidazol-2-yl)isopropylamine 176161-55-0 (R)-2-amino-2-ethylhexan-1-ol 151851-75-1 3-methylenecyclobutanecarbonitrile 15760-35-7 4-tert-butylbenzyl 2-{(2R,3S)-3-[(R)-1-(tert-butyldimethylsilyloxy)ethyl]-2-[(1R,3S)-3-methoxy-2-oxocyclohexyl]-4-oxoazetidin-1-yl}-2-oxoacetate 159593-17-6 methyl (3aR,4R,7aR)-2-methyl-4-[(1S,2R)-1,2,3-triacetoxypropyl]-3a,7a-dihydro-4H-pyrano-[3,4-d]oxazole-6-carboxyrate 78850-37-0 (4S,5R,6R)-5-acetamido-4-amino-6-[(1R,2R)-1,2,3-trihydroxypropyl]-5,6-dihydropyran-2-carboxylic acid 130525-62-1 113 STAT. 2111 Annex (con.) -5- Section A. (con.) 2. (con.) (c). (con.) Product CAS Number pyrazole-1-carboxamidine hydrochloride 4023-02-3 2-acetoxy-5-acetylbenzyl acetate 24085-06-1 (R)-1,2,3.4-tetrahydropapaverine hydrochloride 54417-53-7 trans-2-chloro-3-[4-(4-chlorophenyl)cyclohexyl]-1,4-naphthoquinone 153977-22-1 1,3-dichloroacetone 534-07-6 3,5-dimethylpiperidine 35794-11-7 2,6-diaminopyrimidin-4-ol 56-06-4 1-(2-chloroethyl)piperidinium chloride 2008-75-5 diethyl L-glutamate hydrochloride 1118-89-4 tert-butyl (1R,4S)-4-(hydroxymethyl)cyclopent-2-enylcarbamate 168960-18-7 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one hydrochloride 151257-01-1 tert-butyl 2-{[1 -(2-aminothiazol-4-yl)-2-(benzisothiazol-2-ylthio)-2-oxoethylidenel aminooxy}-2-methyl propionate 89604-92-2 bis[(isopropyloxycarbonyloxy)methyl [(R)-2-(6-amino-9H-purin-9-yl) 1-methylethoxy]methyl phosphonate-fumaric acid (1:1) 202138-50-9 (R)-[2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methylphosphonic acid 147127-20-6 (R)-propylene carbonate 16606-55-6 6-amino-9H-purin-9-ylethanol 707-99-3 (R)-2-(6-amino-9H-purin-9-yl)-1-methylethanol 14047-28-0 chloromethyl isopropyl carbonate 35180-01-9 diethyl (tosyloxy)methylphosphonate 31618-90-3 (R)-3-chloropropane-1,2-diol 57090-45-6 (S)-[(trityloxy)methyl]oxirane 129940-50-7 (S)-2-(2-amino-5-cnlorophenyl)-4-cyclopropyl-1,1,1-trifluorobut-3-yn-2-ol 154598-58-0 10,10-bis[(2-fluoro-4-pyridyl)methyl]anthrone 160588-45-4 (S)-N-{(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl}-3,3-dimethyl-2-(sarcosylamino)butyramide 183556-68-5 (4R,5S,6S,7R)-1-[(3-amino-1H-indazol-5-yl)methyl]-4,7-dibenzyl-3-butyl-5,6-dihydroxyhexanydro-2H-1,3-diazepin-2-one 188978-02-1 (2S)-N-[(R)-1-(1,3-benzodioxol-5-yl)butyl]-3,3-diethyl-2-{4-[(4-methylpiperazin-1-yl)-carbonyl]phenoxy}-4-oxoazetidine-1-carboxamide 157341-41 -8 2-(piperazin-1-yl)pyrimidine 20980-22-7 4-bromo-2,2-diphenylbutanenitrile 39186-58-8 bromomethylcyclopropane 7051-34-5 cyclobutanecarboxylic acid 3721-95-7 2-phenyl-2-pyridylacetonitrile 5005-36-7 5-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one 122852-75-9 4-(2-methyl-2-phenylhydrazino)-5,6-dihydro-2-pyridone 139122-76-2 4,5,6,7-tetrahydrothieno[3,2-clpyridine hydrochloride 28783-41-7 methyl 2-(2-chlorophenyl)-2-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-5-yl)acetate hydrochloride 130209-90-4 2-bromo-2-(2-chlorophenyl)acetic acid 141109-25-3 disodium (2S,3R)-2-hydroxy-3-isobutylsuccinate 157604-22-3 7-amino-3-(2-furoylthiomethyl)-3-cephem-4-carboxylic acid 80370-59-8 methyl 5-chloro-o-anisate 33924-48-0 4-[(4-mesylamino)phenyl]-4-oxobutyric acid 100632-57-3 benzyl (3-fluoro-4-morpholinophenyl)carbamate 168828-81-7 (3R)-3-[(S)-1-(methylamino)ethyl]pyrrolidine 155322-92-2 (4-carboxybutyl)triphenylphosphonium bromide 17814-85-6 (3aS,9aS,9bR)-3a-methyl-6-[2-(2,5,5-trimethyl-1,3-dioxan-2-yl)ethyl]-1,2,4,5,8,9,9a,9boctahydro-3aH-cyclopenta[a]naphthalene-3,7-dione 88128-61-4 2-amino-2',5-dichlorobenzophenone 2958-36-3 21-chloro-16-alpha-methylpregna-1,4,9(11)-triene-3,20-dione 151265-34-8 3,20-dioxopregna-1,4,9(11),16-tetraen-21-yl acetate 37413-91-5 uracil 66-22-8 tetrabutylammonium (6-iodo-1H-purin-2-yl)amide 156126-48-6 (1S,2S,3S)-2,3-bis(benzoyloxymethyl)cyclobutanol 132294-17-8 5-methyluridine 1463-10-1 benzyl (1-carbamoyl-2-hydroxypropyl)carbamate 91558-42-8 5,8-dihydro-1-naphthol 27673-48-9 potassium (R)-N-(3-ethoxy-1-methyl-3-oxoprop-1-enyl)-2-phenylglycine 961-69-3 triethylaniline 33881-72-0 1-[4-(2-dimethylaminoethoxy)[14C]phenyl)]-1,2-diphenylbutan-1-ol 82407-94-1 o-chlorothiophenol 6320-03-2 cytidine 5'-(dihydrogen phosphate) 63-37-6 2-[benzyl(methyl)amino]ethyl acetoacetate 54527-65-0 2-methyl-1-nitrosoindoline 85440-79-5 inosine 5'-disodium phosphate 4691-65-0 4-[1-hydroxy-2-(methylamino)ethyl]phenol--L-tartaric acid (2:1) 16589-24-5 4-phenylpiperidin-4-ol 40807-61-2 1-(4-benzyloxyphenyl)-2-(4-hydroxy-4-phenyl-1-piperidyl)propan-1-one 188591-61-9 7-chloro-2-(4-methoxy-2-methylphenyl)-2,3-dihydro-5H-pyridazino[4,5-b]quinoline-1,4,10-trione, sodium salt 170142-29-7 N'-[N-methoxycarbonyl-L-valyl]-N-[(S)-3,3,3-trifluoro-1-isopropyl-2-oxopropyl]-L-prolinamide 182073-77-4 3-methyl hydrogen 7-chloro-1,4-dihydro-4-oxoquinoline-2,3-dicarboxylate 170143-39-2 (S)-N-(5-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-1H-pyrimido[5,4-b][1,4]thiazin-6-yl)ethyl}-2-thenoyl]-L-glutamic acid 177575-17-6 (S)-2,2-dimethyl-N-hydroxy-4-[4-(4-pyridyloxy)phenylsulfonyl]-1,4-thiazinane-3-carboxamide 192329-42-3 urate oxidase 9002-12-4 (Z)-1-[3-(3-chloro-4-cyclohexylphenyl)prop-2-enyl]hexahydro-1H-azepine hydrochloride 139592-99-7 (Z)-N-[3-(3-chloro-4-cyclohexylphenyl)prop-2-enyl]-N-ethylcyclohexylamine hydrochloride 132173-07-0 trans-2'-fluoro-4-hydroxychalcone O-[(Z)-2-(dimetnylamino)ethyl]oxime-fumaric acid (2:1) 130580-02-8 N',N'-diethyl-2-methyl-N-(6-phenyl-5-propylpyridazin-3-yl)propane-1,2-diamine-fumaric acid (2:3) 137733-33-6 2-{[1-(7-chloro-4-quinolyl)-5-(2,6-dimethoxypnenyl)-1H-pyrazol-3-yl]carbonylamino}-adamantane-2-carboxylic acid 146362-70-1 (S)-N-[4-(4-acetamido-4-phenyl-1-piperidyl)-2-(3,4-dichlorophenyl)butyl]-N- methylbenzamidefumaric acid (1:1) 176381-97-8 N'-{(2R,3S)-5-chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-3-hydroxy-2,3-dihydro-1H-indol-2-ylcarbonyl}-L-prolinamide 150375-75-0 1-(6-chloro-2-pyridyl)-4-piperidylamine hydrochloride 77145-61-0 ethyl ((7S)-7-{[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}-5,6,7,8-tetrahydro-2-naphthyloxy)-acetate hydrochloride 121524-09-2 methyl 0-2-deoxy-6-0-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1,4)-0-beta-D-glucopyranuronosyl-(1,4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-alpha-D- -glucopyranosyl-(1,4)-O-2-O-sulfo-alpha-L-idopyranuronosyl-(1,4)-2-deoxy-2-(sulfoamino)-6-(hydrogensulfate)-alpha-D-glucopyranoside, decasodium salt 114870-03-0 3-{[4-(4-amidinophenyl)thiazol-2-yl][1-(carboxymethyl)-4-piperidyl)amino}propionic acid 180144-61-0 ethyl 3-({4-[4-(N-ethoxycarbonylamidino)phenyl]thiazol-2-yl}[1-(ethoxycarbonylmethyl)-4-pipendyllamino) propionate 190841-79-3 (S)-1-{2-[3-(3,4-dichlorophenyl)-1-(3-isopropoxyphenacyl)-3-piperidyl]ethyl}-4-phenyl-1-azoniabicyclo-[2.2.2]octane chloride 153050-21-6 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidino-1H-pyrazole-3-carboxamide 168273-06-1 (R)-N-(1-{3-[1-benzoyl-3-(3,4-dichlorophenyl)-3-piperidyl]propyl}-4-pnenyl-4-piperidyl)-N-methyl- 113 STAT. 2112 Annex (con.) -6- Section A. (con.) 2. (con.) (c). (con.) Product CAS Number acetamide hydrochloride 173050-51-6 dibenzyl 1-(2,4-difluorophenyl)-2-(1H-1,2,4-triazol-1-yl)-1-(1H-1,2,4-triazol-1-ylmethyl)ethyl phosphate 194602-25-0 (S)-2-{3-[(2-fluorobenzyl)sulfonylamino]-2-oxo-2,3-dihydro-1-pyridyl}-N-(1-formyl-4-guanidinobutyl)acetamide 179524-67-5 4-[4-(4-{4-[(3R,5R)-5-(2,4-difluorophenyl)-5-(1H-1,2,4-triazol-1-ylmethyl)tetrahydrofuran-3-ylmethyloxy]phenyl}piperazin-1-yl)phenyl]-1-[(1S,2S)-1-ethyl-2-hydroxypropyl]-1,2,4-triazol-5(4H)-one 171228-49-2 4-{4-[(11R)-3,10-dibromo-8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]piperidinocarbonylmethyl}piperidine-1-carboxamide 193275-84-2 4-{4-[(11S)-3,10-dibromo-8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]piperidinocarbonylmethyl}piperidine-1-carboxamide 193275-85-3 N-(1-ethyl-1,4-diphenylbut-3-enyl)cyclopropanecarboxamide 137246-21-0 (1S,3S,4S)-1-azabicyclo[2.2.1]heptan-3-ol 142034-92-2 (±)-1-azabicyclo[2.2.1 ]heptan-3-one 21472-89-9 ethyl[3-(4-bromo-2-fluorobenzyl)-7-chloro-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-1-yl] acetate 112733-28-5 2,6-diisopropylphenyl sulfamate 92050-02-7 diethyl (1-cyano-3-methylbutyl)malonate 186038-82-4 2-imino-1,3-thiazol-4-one 556-90-1 3,5-di-tert-butyl-4-hydroxybenzaldehyde 1620-98-0 N-(biphenyl-2-yl)-4-[(2-methyl-4,5-dihydro-1H-imidazo[4,5-d][1]benzazepin-6-yl)carbonyl]benzamidel 79528-39-3 3-(aminomethyl)-5-methylhexanoic acid 128013-69-4 2-(2,4,6-triisopropylphenyl)acetic acid 4276-85-1 N,N'-[dithiobis(o-phenylenecarbonyl)]bis-L-isoleucine 182149-25-3 (1R,4S)-1-azabicyclo[2.2.1]heptan-3-one 142034-97-7 3-amino-7-methyl-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one 70890-50-5 1-ethyl-1,4-diphenylbut-3-enylamine 129140-12-1 sodium 1,2,3-triazole-5-thiolate 59032-27-8 (3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine hydrochloride 183319-69-9 1-[(1S,2S)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]-4-phenylpiperidin-4-ol methanesulfonate trihydrate 189894-57-3 (5R,6S)-6-phenyl-5-[4-(2-pyrrolidinoethoxy)phenyl]-5,6,7,8-tetrahydro-2-naphthol-(-) -tartaric acid (1:1) 190791-29-8 1-[(S)-3-(acetylthio)-2-methylpropionyl]-L-proline 64838-55-7 4'-benzyloxy-2-[(1 -methyl-2-phenoxyethyl)amino]propiophenone hydrochloride 35205-50-6 5-(3-dimethylaminopropyl)-10,11-dihydrodibenzo[a,d]cyclohepten-5-ol 1159-03-1 2-aminoethyldiethylamine 100-36-7 isopropyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-24(E)-(3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy] but-1-enyl}-cyclopentyl]hept-5-enoate 157283-68-6 21-benzyloxy-9-alpha-fluoro-11-beta,17-alpha-dihydroxy-16-alpha-methylpregna-1,4-diene-3,20-dione 150587-07-8 pilocarpine 92-13-7 atropine 51-55-8 4-nitrobenzyl (4R,5R,6S)-3-(diphenoxyphosphoryloxy)-6-[(R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate 90776-59-3 2-aminopropane-1,3-diol 534-03-2 methyl 4-(bromomethyl)benzoate 2417-72-3 2-butylimidazole-5-carbaldehyde 68282-49-5 ethyl hydrogen (2-thienylmethyl)malonate 143468-96-6 4-(2-butyl-5-formylimidazol-1-ylmethyl)benzoic acid 152146-59-3 2,6-dichloro-4-methylnicotinonitrile 875-35-4 3,5-diacetamido-2,4,6-triiodobenzoic acid dihydrate 50978-11 -5 2,2,2-trifluoroethanol 75-89-8 13-ethyl-17-alpha-hydroxy-18,19-dinorpregn-4-en-20-yn-3-one oxime 53016-31-2 estropipate 7280-37-7 4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide 180200-68-4 17-alpna-hydroxy-3,20-dioxopregna-4,9(11)-diene-21-yl acetate 7753-60-8 hemocyanins, megathura crenulata, reaction products with 1-O-[O-2-acetamido-2-deoxy-beta-D-galactopyranosyl-(1,4)-O-(N-acetyl-alphaneuraminosyl)-(2,3)]-O-beta-D-galactopyranosyl-(1,4)-beta-D-glucopyranose 195993-11 -4 1-(28-{O-D-apio-beta-D-furanosyl-(1,3)-O-beta-D-xylopyranosyl-(1,4)-O-6-deoxy-alpha-L-mannopyranosyl)-(1,2)-4-O-[5-(5-a(pha-L-arabinofuranosyloxy-3-hydroxy-6-methyloctanoyloxy)-3-hydroxy-6-methyloctanoyl]-6-deoxy-beta-D-galactopyranosyloxy}-16-alpha-hydrox 141256-04-4 1-O-[O-(N-acetyl-alpha-neuraminosyl)-(2,3)-O-[O-beta-D-galactopyranosyl-(1,3)-2 -acetamido-2-deoxy-beta-D-galactopyranosyl-(1,4)]-O-beta-D-galactopyranosyl-(1,4)-beta-D-glucopyranosyl]ceramide 104443-62-1 1-O-[O-2-acetamido-2-deoxy-beta-D-galactopyranosyl-(1,4)-O-(N-acetyl-alphaneuraminosyl)-(2,3)-O-beta-D-galactopyranosyl-(l ,4)-beta-D-glucopyranosyl]ceramide 104443-57-4 N-{[(1R,2R)-1-[O-(N-acetyl-alpha-neuraminosyl)-(2,3)-O-2-acetamido-2-deoxybeta-D-galactopyranosyl-(1,4)-O-beta-D-galactopyranosyl-(1,4)-beta-D-glucopyranosyloxymetnyl]-2-hydroxy-3-formylpropyl}stearamide 196085-62-8 ferristene 155773-56-1 codeine phosphate hemihydrate 41444-62-6 trans-1-benzoyl-4-phenyl-L-proline 120851-71-0 5-methyluridine hemihydrate 25954-21-6 5'-benzoyl-2',3'-didehydro-3'-deoxythymidine 122567-97-9 3',5'-anhydrothymidine 38313-48-3 4'-(benzyloxycarbonyl)-4'-demethylepipodophyllotoxin 23363-33-9 2,3,4,6-tetra-O-benzyl-1-O-(trimethylsilyl)-b-D-glucose 80312-55-6 2,3,4,6-tetra-O-benzyl-D-glucose 4132-28-9 6-iodo-1H-purin-2-ylamine 19690-23-4 (1R,2R,3S)-2-amino-9-[2,3-bis(benzoyloxymethyl)cyclobutyl]-9H-purin-6-one 156126-53-3 (1RS,2RS,3SR)-2,3-bis(benzoyloxymethyl)cyclobutylamine 151807-53-3 (1RS,2RS,3RS]-2,3-bis(benzoyloxymethyl)cyclobutanol 127759-90-4 (1R,2R,3S)-9-[2.3-bis(benzoyloxymethyl)cyclobutyl]-6-iodo-9H-purin-2-ylamine 156126-89-3 (2S,3S)-2,3-bis(benzoyloxymethyl)cyclobutanone 132294-16-7 (S)-5-(1,3-dioxolan-4-yl)-2-aminovaleric acid 170242-34-9 N,N'-bis(trifluoroacetyl)-DL-homocystine 105996-54-1 (S)-2-(acetylthio)-3-phenylpropionic acid-dicyclohexylamine (1:1) 157521-26-1 methyl (4S.7S, 10aS)-4-amino-5-oxooctahydro-7H-pyrido[2,1-b][1,3]thiazepine-7-carboxylate 167304-98-5 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-ylmethyl)biphenyl-2-carbonitrile 138401-24-6 DL-5-(1,2-dithiolan-3-yl)valeramide 3206-73-3 4-(4-methoxyphenyl)butan-2-one 104-20-1 tetraisopropyl methylenediphosphonate 1660-95-3 (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 74163-81-8 (S)-N-tert-butyl-1,2,3,4-teirahydroisoquinoline-3-carboxamide hydrochloride 149057-17-0 (S)-N-tert-butyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide sulfate 186537-30-4 (3S)-tetrahydrofuran-3-yl (1S,2R)-3-[(4-aminophenylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate 161814-49-9 6-benzyl-1-(ethoxymethyl)-5-isopropylpyrimidine-2,4(1H,3H)-dione 149950-60-7 (2R,5S)-4-amino-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one 143491-57-0 3'-azido-2',3'-dideoxy-5-methylcytidine hydrochloride 108895-45-0 113 STAT. 2113 Annex (con.) -7- Section A. (con.) 2. (con.) (c). (con.) Product CAS Number (2R,4R)-4-(2,6-diamino-9H-purin-9-yl)-1,3-dioxolan-2-ylmethanol 145514-04-1 (4R,5S,6St7R)-1,3-bis(3-aminobenzyl)-4,7-dibenzyl-5,6-dihydroxyhexahydro-2H-1,3-diazepin-2-one dimethanesulfonate 177932-89-7” Section B. Effective with respect to articles entered, or withdrawn from warehouse for consumption, on or after April 1, 1997, the following technical corrections are made to the enumerated subheading: 1. For subheading 2918.13.50, the Rates of Duty 1-Special subcolumn is modified by inserting, in alphabetical order, the symbol “K” in the parentheses following the “Free” rate of duty in such subcolumn. 2. The Pharmaceutical Appendix to the HTS is modified by adding to Table 3 of the Appendix the following product, with the product name inserted in alphabetical order in the “Product” column and its Chemical Abstracts Service

(CAS)registry number in the “CAS No.” column: " “1-{N2-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-N6-trifluoroacetyllsyl}proline 103300-91-0“ " Section C. Effective with respect to articles entered, or withdrawn from warehouse for consumption, on or after January 1, 1995, the following technical corrections are made to the enumerated subheadings: For subheadings 2904.90.47, 2917.39.30, 2918.29.20, 2935.00.05, and 3402.20.10, the Rates of Duty 1-Special subcolumn is modified by inserting, in alphabetical order, the symbol “K” in the parentheses following the “Free” rate of duty in such subcolumn for each such subheading. 7208 July 7, 1999 To Facilitate Positive Adjustment to Competition From Imports of Lamb Meat By the President of the United States of America A Proclamation Proclamation 7208 of July 7, 1999 To Facilitate Positive Adjustment to Competition From Imports of Lamb Meat By the President of the United States of America A Proclamation 1. On April 5, 1999, the United States International Trade Commission (USITC) transmitted to the President a unanimous affirmative determination in its investigation under section 202 of the Trade Act of 1974, as amended (the “Trade Act”) (19 U.S.C. 2252), with respect to imports of fresh, chilled, or frozen lamb meat, provided for in heading 0204 of the Harmonized Tariff Schedule of the United States (HTS). Under section 202 of the Trade Act, the USITC determined that such lamb meat is being imported into the United States in such increased quantities as to be a substantial cause of the threat of serious injury to the domestic industry producing a like or directly competitive article. Further, the USITC, pursuant to section 311(a) of the North American Free Trade Agreement Implementation Act (the “NAFTA Implementation Act”) (19 U.S.C. 3371(a)), made negative findings with respect to imports of lamb meat from Canada and Mexico. The USITC also transmitted to the President its recommendation made pursuant to section 202(e) of the Trade Act with respect to the action that would address the threat of serious injury to the domestic industry and be most effective in facilitating the efforts of the domestic industry to make a positive adjustment to import competition.113 STAT. 2114 2. Pursuant to section 203 of the Trade Act (19 U.S.C. 2253), and after taking into account the considerations specified in section 203(a)(2) of the Trade Act, I have determined to implement action of a type described in section 203(a)(3). However, pursuant to section 312(a) of the NAFTA Implementation Act (19 U.S.C. 3372(a)), I have determined that imports from Canada and Mexico, considered individually, do not account for a substantial share of total imports and do not contribute importantly to the threat of serious injury found by the USITC. Accordingly, pursuant to section 312(b) of the NAFTA Implementation Act (19 U.S.C. 3372(b)), I have excluded lamb meat the product of Canada or Mexico from the action I am taking under section 203 of the Trade Act. 3. Such action shall take the form of a tariff-rate quota on imports of fresh, chilled, or frozen lamb meat, provided for in HTS subheadings 0204.10.00, 0204.22.20, 0204.23.20, 0204.30.0G, 0204.42.20, and 0204.43.20, imposed for a period of 3 years plus 1 day, with annual increases in the within-quota quantities in the second and third years, as provided for in the annex to this proclamation. 4. Except for products of Canada, Mexico, Israel, beneficiary countries under the Caribbean Basin Economic Recovery Act (CBERA) and the Andean Trade Preference Act (ATPA), and other developing countries that have accounted for a minor share of lamb meat imports, which shall all be excluded from this restriction, such tariff-rate quota shall apply to imports of lamb meat from all other countries and the inquota quantity in each year shall be allocated among such countries. Pursuant to section 203(a)(1)(A) of the Trade Act (19 U.S.C. 2253(a)(1)(A)), I have further determined that these actions will facilitate efforts by the domestic industry to make a positive adjustment to import competition and provide greater economic and social benefits than costs. 5. Section 604 of the Trade Act, as amended (19 U.S.C. 2483), authorizes the President to embody in the HTS the substance of the relevant provisions of that Act, and of other acts affecting import treatment, and actions thereunder, including the removal, modification, continuance, or imposition of any rate of duty or other import restriction. NOW, THEREFORE, I, WILLIAM J. CLINTON, President of the United States of America, acting under the authority vested in me by the Constitution and the laws of the United States of America, including but not limited to sections 203 and 604 of the Trade Act, and section 301 of title 3, United States Code, do proclaim that:

(1)In order to establish a tariff-rate quota on imports of fresh, chilled, or frozen lamb meat classified in HTS subheadings 0204.10.00, 0204.22.20, 0204.23.20, 0204.30.00, 0204.42.20, and 0204.43.20, subchapter III of chapter 99 of the HTS is modified as provided in the annex to this proclamation.

(2)Such imported lamb meat that is the product of Canada, Mexico, Israel, and of beneficiary countries under the CBERA and the ATPA, and of developing countries listed in general note 4(a) to the HTS, shall be excluded from the tariff-rate quota established by this proclamation, and such imports shall not be counted toward the tariff-rate quota limits that trigger the over-quota rates of duty.

(3)In the event that a quota quantity established by this proclamation and allocated to a country or to “other countries” is significantly 113 STAT. 2115underutilized, the United States Trade Representative is authorized to reallocate all or part of the unfilled portion of such quota quantity to any other country or countries and, upon publication of notice in the **Federal Register**, to modify the HTS provisions created by the annex to this proclamation to reflect any such reallocation.

(4)Any provisions of previous proclamations and Executive orders that are inconsistent with the actions taken in this proclamation are superseded to the extent of such inconsistency.

(5)The modifications to the HTS made by this proclamation, including the annex hereto, shall be effective with respect to goods entered, or withdrawn from warehouse for consumption, on or after 12:01 a.m. e.d.t. on July 22, 1999, and shall continue in effect as provided in the annex to this proclamation, unless such actions are earlier expressly modified or terminated. IN WITNESS WHEREOF, I have hereunto set my hand this seventh day of July, in the year of our Lord nineteen hundred and ninety-nine, and of the Independence of the United States of America the two hundred and twenty-fourth. WILLIAM J. CLINTON 113 STAT. 2116 ANNEX Modifications to the Harmonized Tariff Schedule of the United States

(a)Effective with respect to goods entered, or withdrawn from warehouse for consumption, on or after July 22, 1999, subchapter III of chapter 99 of the Harmonized Tariff Schedule of the United States is modified by inserting in numerical sequence the following new U.S. note, subheadings and superior text thereto, with the language inserted in the columns entitled “Heading/Subheading”, “Article Description”, “Rates of Duty 1-General”, “Rates of Duty 1-Special”, and “Rates of Duty 2”, respectively. " “8. For purposes of the subheadings enumerated below, the in-quota quantities for fresh, chilled or frozen lamb meat shall be allocated as follows: Subheadings Country or Countries Allocation 9903.02.01 Australia 17,139,582 New Zealand 14,481,603 Other countries 229,966 9903.02.03 Australia 17,600,931 New Zealand 14,871,407 Other countries 236,155 9903.02.05 Australia 18,062,279 New Zealand 15,261,210 Other countries 242,346 Carcasses and half-carcasses of lamb (provided for in subheading 0204.10.00 or 0204.30.00), other lamb cuts with bone in (provided for in subheading 0204.22.20 or 0204.42.20), and boneless lamb meat (provided for in subheading 0204.23.20 or 0204.43.20), all the foregoing fresh, chilled or frozen, except products of Canada, of Mexico, of Israel, of developing countries enumerated in general note 4(a) to this schedule, of beneficiary countries under the Caribbean Basin Economic Recovery Act (as enumerated in general note 7(a) to this schedule) or of beneficiary countries under the Andean Trade Preference Act (as enumerated in general note 11(a) to this schedule): If entered during the period from July 22, 1999, through July 21, 2000 inclusive: 9903.02.01 In quantities not in excess of 31,851,151 kg 9% 15.4¢/kg 9903.02.02 Other 40% 15.4¢/kg + 40% [Carcasses...:] If entered during the period from July 22, 2000, through July 21, 2001, inclusive: 9903.02.03 In quantities not in excess of 32,708,493 kg 6% 15.4¢/kg 9903.02.04 Other 32% 15.4¢/kg + 32% If entered during the period from July 22, 2001, through July 22, 2002, inclusive: 9903.02.05 In quantities not in excess of 33,565,835 kg 3% 15.4¢/kg 9903.02.06 Other 24% 15.4¢/kg + 24%” " 7209 July 16, 1999 Captive Nations Week, 1999 By the President of the United States of America A Proclamation

Connectionstraces to 6

Traces to 6 documents

U.S. Code